Director

David Kirn, M.D.

Co-Founder, President, Chief Executive Officer and Director·4D Molecular Therapeutics, Inc.

About

Co-founder of 4DMT; CEO and director since the company's inception in 2013 and President since January 2026. Former Executive Chairman until August 2020. Adjunct Professor of Bioengineering and Molecular & Cellular Biology at U.C. Berkeley and co-founder of the U.C. Berkeley Life Sciences Entrepreneurship Center. Previously co-founder and Executive Chairman of Ignite Immunotherapy and held senior development roles at Onyx Pharmaceuticals and Celgene.

Since 2013
Tenure 13 yrs

Also at 4D Molecular Therapeutics, Inc.

JP John F. Milligan, Ph.D. Director and Executive Chairman JM Jacob Chacko, M.D., MBA Director SM Susannah Gray, MBA Director CP Charles P. Theuer, M.D., Ph.D. Director NM Nancy Miller-Rich Director SM Shawn Cline Tomasello, MBA Director

Roles

Organization Role Dates Details
4D Molecular Therapeutics, Inc. Co-Founder, President, Chief Executive Officer and Director 2013–present Current role

Related

Source: 4D Molecular Therapeutics, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo